F. Vallone

SLV‐404, an anti‐RYK antibody–drug conjugate, is effective in Richter transformation patient‐derived xenografts

Abstract Richter transformation (RT), a highly aggressive lymphoma arising from a preexisting chronic lymphocytic leukemia, represents a major unmet clinical need. Recent data have shown that an antibody–drug conjugate (ADC) targeting the cell‐surface pseudokinase ROR1 is effective in RT patients. In this work, we expl...